Lead Advisor Eaton Capital supports CardioLife’s Left Ventricular Assist Device Revolution in India

At Eaton Capital Partners (ECP), we are proud to be lead advisor to CardioLife MedTech Pty Ltd. on their mission to transform global cardiac care. ECP has completed a fully subscribed Seed Round and secured a pivotal AUD $5 million commitment from Andhra Pradesh MedTech Zone (AMTZ), India’s premier MedTech innovation hub.

Impact-Driven Innovation

For ECP, we see this as a defining opportunity to turn capital into meaningful change. Our mandate is to mobilise private and public investment to deliver measurable outcomes in health, climate and sustainable economic growth. CardioLife’s EasyHeart embodies these principles by tackling a critical challenge, the prohibitive cost and long development cycles of traditional Left Ventricular Assist Device’s (LVAD’s).

In the current climate, Western LVAD solutions typically cost over USD $100,000 and take up to 12 years to reach patients, delaying access for patients who need them most. CardioLife is redefining this model by leveraging India’s advanced MedTech ecosystem to fast-track innovation. Through this approach, the EasyHeart device aims to secure Indian regulatory approval in under 24 months which is nearly half the time of conventional regulatory pathways and will deliver a device at less than 50% of global market costs without compromising quality or safety.

Why India? Why Now?

India offers a unique combination of scale, cost-efficiency, and technical capability that makes it an ideal launchpad for disruptive healthcare solutions. With an estimated 500,000+ patients requiring mechanical circulatory support annually, the Indian market provides an immediate, high-impact innovative product for an underserved market. Through its partnership with AMTZ, CardioLife gains access to world-class testing facilities, ISO-certified prototyping, and leading clinical networks –  which are all within an ecosystem specifically designed to accelerate MedTech development and regulatory approval.

Strategic Partnership for Global Scale 

Eaton Capital’s role spans capital raising, cross-border structuring, and long-term growth planning, ensuring that CardioLife’s India-first approach accelerates not only clinical adoption but also global market entry. This strategy creates value delivering both commercial success and life-saving technology for marginalised populations.

Capital with Purpose 

This project reflects ECP’s core philosophy, investing where financial returns align with measurable social impact. Our partnership with CardioLife reflects our commitment to ethical, sustainable investment and to advancing innovation that improves lives at scale.

By combining CardioLife’s India-first strategy with Australian R&D and ECP’s impact-driven approach, we are setting a new benchmark for how MedTech innovation can be delivered: faster, more affordable, and globally relevant.

Thenura Sonnadara is an analyst at Eaton Capital Partners. Discover more about Eaton Capital Partners at www.eatoncapital.com.au. Join us in building a sustainable, prosperous future.